Reference:GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 Schedule 3 Part 1 1.: Difference between revisions
From GxPlex
Gxplex admin (talk | contribs) m 1 revision imported |
imported>GxPlexBot Import from GxPlex Excel |
||
| Line 6: | Line 6: | ||
1. | 1. | ||
|RefLanguage=EN | |RefLanguage=EN | ||
| | |RefTags=TAG-00134-Eth-kom ++ TAG-00135-Inv-ntr ++ TAG-00059-Reg-lat | ||
| | |RefModule=2 | ||
| | |RefUnit=2.3.3 | ||
}} | }} | ||
| Line 16: | Line 16: | ||
|- | |- | ||
! colspan="2" class="gplx-infobox-header" | Reference Details | ! colspan="2" class="gplx-infobox-header" | Reference Details | ||
|- | |||
! Module | |||
| Module 2 β Unit 2.3.3 | |||
|- | |- | ||
! Scope | ! Scope | ||
| Line 34: | Line 37: | ||
| Β | | Β | ||
|- | |- | ||
! Tags | ! Tags | ||
| Β | | [[Glossary:TAG-00134-Eth-kom|Ethics committee]], [[Glossary:TAG-00135-Inv-ntr|Trial site]], [[Glossary:TAG-00059-Reg-lat|Regulatory submission]] | ||
|- | |||
|- | |||
| Β | |||
|- | |- | ||
! Comment | ! Comment | ||
Revision as of 17:29, 15 July 2026
| Document information | |
|---|---|
| Reference | GBR The Medicines for Human Use (Clinical Trials) Regulations 2004 01-May-2004 |
| Validity area | GBR |
| Scope(s) | HM |
| Document name | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Version / Revision | 01-May-2004 |
| Status | Current |
| Document type | Legal act |
| Language(s) | EN |
| Description | The Medicines for Human Use (Clinical Trials) Regulations 2004 |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 2 β Unit 2.3.3 |
| Scope | HM |
| Document part | Schedule 3
Part 1 1. |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Ethics committee, Trial site, Regulatory submission |
| Comment | Information required for ethics committee opinion application |
Content
APPLICATION FOR ETHICS COMMITTEE OPINION 1. An application document including the following information or, in each case, an explanation of why that information is not being providedβ [β¦] (t)details of any proposed trial site and its suitability for conducting the trial.
